|
ctDNA-based genomic landscape analysis to evaluate molecular brake and gatekeeper mutations in FGFR2 alterations. |
| |
|
Employment - Kinnate Biopharma; Plexxikon |
Stock and Other Ownership Interests - Daiichi Sankyo/UCB Japan; Kinnate Biopharma |
Travel, Accommodations, Expenses - Kinnate Biopharma; Plexxikon |
| |
|
No Relationships to Disclose |
| |
|
Employment - Kinnate Biopharma |
Stock and Other Ownership Interests - Kinnate Biopharma |
| |
|
Employment - Guardant Health |
Stock and Other Ownership Interests - Guardant Health |
Patents, Royalties, Other Intellectual Property - RWE selection patent application pending |
Travel, Accommodations, Expenses - Guardant Health |
| |
|
Employment - Guardant Health |
Stock and Other Ownership Interests - Guardant Health |
| |
|
Employment - Kinnate Biopharma |
Stock and Other Ownership Interests - Kinnate Biopharma |